David Shvammental, director of the American-Jewish Transatlantic Institute in Brussels, says: 

"In fact, the two-year debate was not about the essence of the agreement, but about politics. For Some MEPs their opposition to Israel's political position is more important than caring for the health of their constituents and the modernization health systems in their countries. Israeli pharmaceutical companies are at the forefront of research. They produce cheaper and better quality of medicines. European patients will simply benefit from the ratification ACAA ".

Source: Mignews.com